Newco Glycocore Pharma Srl is setting out to raise €10 million (US$11.2 million) in a series A round to take a novel approach to treating inflammatory respiratory diseases into the clinic, starting with a phase I/Ib trial in idiopathic pulmonary fibrosis.
EG 427 SAS has added a further a further €5 million (US$5.6 million) to its series A, closing the round at €18 million and setting the stage for the first clinical trial of a gene therapy in the treatment of a chronic disorder.
Sonio SAS closed its series A fundraising round raising $14 million that will go some way in helping the company deliver on its mission to improve access to quality pregnancy monitoring for women everywhere through its software-as-a-service (SaaS) platform. Sonio has developed an artificial intelligence (AI) prenatal screening solution that automates ultrasound reporting while providing image quality control and detection of potential anomalies. The capital raise was led by Cross-Border Impact Ventures, a North American impact fund dedicated to the health of women and children.
Tenpoint Therapeutics Ltd. raised $70 million in a series A funding round to pursue ambitious plans to reverse vision loss using both ex vivo cell engineering and in vivo cell reprogramming approaches.
Crossbow Therapeutics Inc. has launched with US$80 million in series A funding. The financing will allow Crossbow to advance the development of novel therapies that potently target peptide-loaded major histocompatibility complexes on cancer cells, using antibodies that mimic T-cell receptors (TCR).
Taking aim at the elusive place where stubborn cancer cells multiply, Crossbow Therapeutics Inc. has launched with $80 million in funds through a series A round. The Cambridge, Mass.-based company plans to advance its novel therapies, which mimic T-cell receptors and target peptide-loaded major histocompatibility complexes on cancer cells. If all goes well, the first product will be in the clinic in 2025.
Tolerogenixx GmbH raised €7 million (US$7.6 million) in an extension to its series A round, which will enable it to continue phase IIb development of a cell therapy that induces donor-specific immune tolerance in kidney transplant recipients. At the same time, the company disclosed five-year follow-up data from a phase Ib trial of the therapy, which demonstrated that recipients continue to have stable graft function and to avoid acute rejection and severe opportunistic infections while on a reduced regimen of immunosuppressive drugs.
Luminopia Inc. reeled in $16 million in an oversubscribed series A financing led by U.S. Venture Partners. The funds will support full commercial launch of the company’s U.S. FDA-cleared digital therapeutic for the treatment of children ages 4-7 with amblyopia. “We are thrilled to announce the successful close of our oversubscribed series A round, which will allow us to advance our mission of pioneering a new class of treatments for the 15 million Americans who suffer from neuro-visual disorders,” said Scott Xiao, Luminopia’s co-founder and CEO.
The near $50 million cash injection Nvision Imaging Technologies GmbH recently received is “instrumental” as it will allow the company to take its hyperpolarized magnetic resonance imaging (MRI) technology to labs worldwide, CEO Sella Brosh told BioWorld. The German startup’s quantum technology makes MRI imaging up to 100,000 times more precise which will allow for the earlier diagnosis of cancer, better assessment of the risks involved and the ability to assess in a matter of days, whether treatment is working.
RSS
